Targeting and killing specific cells discriminately has been the goal of targeted therapy dating back to the era of Paul Ehrlich. The discovery of cancer stem cells has caused a paradigm shift within the cancer field and provided an opportunity to use targeted therapies such as targeted toxins to bind and kill these cells selectively. A number of targeted toxins have been developed against recently identified cancer stem cell markers. In this review we discuss the development and current status of these exciting novel drugs and their potential use to combat drug-refractory relapse.
References
[1]
Kornek, G.; Selzer, E. Targeted therapies in solid tumours: pinpointing the tumour’s Achilles heel. Curr. Pharm. Des. 2009, 15, 207–242, doi:10.2174/138161209787002906.
Madhumathi, J.; Verma, R.S. Therapeutic targets and recent advances in protein immunotoxins. Curr. Opin. Microbiol. 2012, 15, 300–309.
[4]
Choudhary, S.; Mathew, M.; Verma, R.S. Therapeutic potential of anticancer immunotoxins. Drug Discov. Today 2011, 16, 495–503, doi:10.1016/j.drudis.2011.04.003.
[5]
Eyler, C.E.; Rich, J.N. Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 2008, 26, 2839–2845, doi:10.1200/JCO.2007.15.1829.
[6]
Moncharmont, C.; Levy, A.; Gilormini, M.; Bertrand, G.; Chargari, C.; Alphonse, G.; Ardail, D.; Rodriguez-Lafrasse, C.; Magne, N. Targeting a cornerstone of radiation resistance: Cancer stem cell. Cancer Lett. 2012, 322, 139–147, doi:10.1016/j.canlet.2012.03.024.
[7]
Bonnet, D.; Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3, 730–737, doi:10.1038/nm0797-730.
[8]
Ten Cate, B.; de Bruyn, M.; Wei, Y.; Bremer, E.; Helfrich, W. Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology. Curr. Drug Targets 2010, 11, 95–110, doi:10.2174/138945010790031063.
[9]
Frankel, A.; Liu, J.S.; Rizzieri, D.; Hogge, D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk. Lymphoma 2008, 49, 543–553, doi:10.1080/10428190701799035.
[10]
Du, X.; Ho, M.; Pastan, I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J. Immunother. 2007, 30, 607–613, doi:10.1097/CJI.0b013e318053ed8e.
[11]
Boman, B.M.; Wicha, M.S. Cancer stem cells: A step toward the cure. J. Clin. Oncol. 2008, 26, 2795–2799.
[12]
Sales, K.M.; Winslet, M.C.; Seifalian, A.M. Stem cells and cancer: An overview. Stem Cell Rev. 2007, 3, 249–255, doi:10.1007/s12015-007-9002-0.
[13]
Zollar, M. CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? Nat. Rev. Cancer 2011, 11, 254–267, doi:10.1038/nrc3023.
[14]
Orian-Rousseau, V. CD44, a therapeutic target for metastasising tumours. Eur. J. Cancer 2010, 46, 1271–1277, doi:10.1016/j.ejca.2010.02.024.
[15]
B？rjesson, P.K.; Postema, E.J.; Roos, J.C.; Colnot, D.R.; Marres, H.A.; van Schie, M.H.; Stehle, G.; de Bree, R.; Snow, G.B.; Oyen, W.J.; et al. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 2003, 9, 3961S–3972S.
[16]
Sauter, A.; Kloft, C.; Gronau, S.; Bogeschdorfer, F.; Erhardt, T.; Golze, W.; Schroen, C. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int. J. Oncol. 2007, 30, 927–935.
[17]
Riechelmann, H.; Sauter, A.; Golze, W.; Hanft, G.; Schroen, C.; Hoermann, K.; Erhardt, T.; Gronau, S. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol. 2008, 44, 823–829, doi:10.1016/j.oraloncology.2007.10.009.
[18]
Trzpis, M.; McLaughlin, P.M.; de Leij, L.M.; Harmsen, M.C. Epithelial cell adhesion molecule: More than a carcinoma marker and adhesion molecule. Am. J. Pathol. 2007, 171, 386–395, doi:10.2353/ajpath.2007.070152.
[19]
Imrich, S.; Hachmeister, M.; Gires, O. EpCAM and its potential role in tumor-initiating cells. Cell Adh. Migr. 2012, 6, 30–38, doi:10.4161/cam.18953.
[20]
Van der Gun, B.T.; Melchers, L.J.; Ruiters, M.H.; de Leij, L.F.; McLaughlin, P.M.; Rots, M.G. EpCAM in carcinogenesis: The good, the bad or the ugly. Carcinogenesis 2010, 31, 1913–1921, doi:10.1093/carcin/bgq187.
[21]
Yamashita, T.; Ji, J.; Budhu, A.; Forgues, M.; Yang, W.; Wang, H.Y.; Jia, H.; Ye, Q.; Qin, L.; Wauthier, E.; et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009, 136, 1012–1024.
[22]
Takahashi-Yanaga, F.; Kahn, M. Targeting Wnt signaling: Can we safely eradicate cancer stem cells? Clin. Cancer Res. 2010, 16, 3153–3162, doi:10.1158/1078-0432.CCR-09-2943.
[23]
Stish, B.J.; Chen, H.; Shu, Y.; Panoskaltsis-Mortari, A.; Vallera, D.A. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin. Cancer Res. 2007, 13, 3058–3067, doi:10.1158/1078-0432.CCR-06-2454.
[24]
Moldenhauer, G.; Salnikov, A.V.; Lüttgau, S.; Herr, I.; Anderl, J.; Faulstich, H. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J. Natl. Cancer Inst. 2012, 104, 622–634, doi:10.1093/jnci/djs140.
[25]
Hidalgo, M. Pancreatic cancer. N. Engl. J. Med. 2010, 362, 1605–1617.
[26]
Martin-Killias, P.; Stefan, N.; Rothschild, S.; Plückthun, A.; Zangemeister-Wittke, U. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clin. Cancer Res. 2011, 17, 100–110, doi:10.1158/1078-0432.CCR-10-1303.
[27]
Kowalski, M.; Entwistle, J.; Cizeau, J.; Niforos, D.; Loewen, S.; Chapman, W.; MacDonald, G.C. A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients. Drug Des. Devel. Ther. 2010, 4, 313–320.
[28]
Kowalski, M.; Guindon, J.; Brazas, L.; Moore, C.; Entwistle, J.; Cizeau, J.; Jewett, M.A.; MacDonald, G.C. A phase II study of oportuzumab monatox: An immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin. J. Urol. 2012, 188, 1712–1718.
[29]
MacDonald, G.C.; Rasamoelisolo, M.; Entwistle, J.; Cizeau, J.; Bosc, D.; Cuthbert, W.; Kowalski, M.; Spearman, M.; Glover, N. A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Des. Devel. Ther. 2009, 2, 105–114.
[30]
Entwistle, J.; Brown, J.G.; Chooniedass, S.; Cizeau, J.; Macdonald, G.C. Preclinical Evaluation of VB6-845: An Anti-EpCAM Immunotoxin with Reduced Immunogenic Potential. Cancer Biother. Radiopharm. 2012, 27, 582–592, doi:10.1089/cbr.2012.1200.271.
[31]
Ferrandina, G.; Petrillo, M.; Bonanno, G.; Scambia, G. Targeting CD133 antigen in cancer. Expert Opin. Ther. Targets 2009, 13, 823–837, doi:10.1517/14728220903005616.
[32]
Rappa, G.; Fodstad, O.; Lorico, A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 2008, 26, 3008–3017, doi:10.1634/stemcells.2008-0601.
[33]
Mak, A.B.; Nixon, A.M.; Kittanakom, S.; Stewart, J.M.; Chen, G.I.; Curak, J.; Gingras, A.C.; Mazitschek, R.; Neel, B.G.; Stagljar, I.; et al. Regulation of CD133 by HDAC6 Promotes β-Catenin Signaling to Suppress Cancer Cell Differentiation. Cell Rep. 2012, 2, 951–963, doi:10.1016/j.celrep.2012.09.016.
[34]
Takenobu, H.; Shimozato, O.; Nakamura, T.; Ochiai, H.; Yamaguchi, Y.; Ohira, M.; Nakagawara, A.; Kamijo, T. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 2011, 30, 97–105, doi:10.1038/onc.2010.383.
[35]
Damek-Poprawa, M.; Volgina, A.; Korostoff, J.; Sollecito, T.P.; Brose, M.S.; O’Malley, B.W., Jr.; Akintoye, S.O.; DiRienzo, J.M. Targeted inhibition of CD133+ cells in oral cancer cell lines. J. Dent. Res. 2011, 90, 638–645.
[36]
Waldron, N.N.; Kaufman, D.S.; Oh, S.; Inde, Z.; Hexum, M.K.; Ohlfest, J.R.; Vallera, D.A. Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer. Mol. Cancer Ther. 2011, 10, 1829–1838, doi:10.1158/1535-7163.MCT-11-0206.
[37]
Swaminathan, S.K.; Olin, M.R.; Forster, C.L.; Cruz, K.S.; Panyam, J.; Ohlfest, J.R. Identification of a novel monoclonal antibody recognizing CD133. J. Immunol. Methods 2010, 361, 110–115, doi:10.1016/j.jim.2010.07.007.
Skubitz, A.P.N.; Taras, E.P.; Boylan, K.L.M.; Waldron, N.N.; Oh, S.; Panoskaltsis-Mortari, A.; Vallera, D.A. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol. Oncol. 2013. submitted.
[40]
Rutella, S.; Bonanno, G.; Marone, M.; De Ritis, D.; Mariotti, A.; Voso, M.T.; Scambia, G.; Mancuso, S.; Leone, G.; Pierelli, L. Identification of a novel subpopulation of human cord blood CD34- CD133- CD7- CD45t lineage-cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15. J. Immunol. 2003, 171, 2977–2988.
[41]
Suuronen, E.J.; Wong, S.; Kapila, V.; Waghray, G.; Whitman, S.C.; Mesana, T.G.; Ruel, M. Generation of CD133+ cells from CD133- peripheral blood mononuclear cells and their properties. Cardiovasc. Res. 2006, 70, 126–135, doi:10.1016/j.cardiores.2006.01.014.
[42]
Smith, L.M.; Nesterova, A.; Ryan, M.C.; Duniho, S.; Jonas, M.; Anderson, M.; Zabinski, R.F.; Sutherland, M.K.; Gerber, H.P.; Van Orden, K.L.; et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br. J. Cancer 2008, 99, 100–109, doi:10.1038/sj.bjc.6604437.
[43]
Oh, S.; Stish, B.J.; Vickers, S.M.; Buchsbaum, D.J.; Saluja, A.K.; Vallera, D.A. A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer. Pancreas 2010, 39, 913–922, doi:10.1097/MPA.0b013e3181cbd908.
[44]
Weyergang, A.; Selbo, P.K.; Berstad, M.E.; Bostad, M.; Berg, K. Photochemical internalization of tumor-targeted protein toxins. Lasers Surg. Med. 2011, 43, 721–733.
[45]
Escoffre, J.M.; Mannaris, C.; Geers, B.; Novell, A.; Lentacker, I.; Averkiou, M.; Bouakaz, A. Doxorubicin liposome-loaded microbubbles for contrast imaging and ultrasound triggered drug delivery. IEEE Trans. Ultrason. Ferroelectr. Freq. Control. 2013, 60, 78–87, doi:10.1109/TUFFC.2013.2539.
[46]
Hassan, R.; Broaddus, V.C.; Wilson, S.; Liewehr, D.J.; Zhang, J. Anti-Mesothelin Immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin. Cancer Res. 2007, 13, 7166–7171, doi:10.1158/1078-0432.CCR-07-1592.
[47]
Pearson, J.W.; Sivam, G.; Manger, R.; Wiltrout, R.H.; Morgan, A.C., Jr.; Longo, D.L. Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice. Cancer Res. 1989, 49, 4990–4995.
